Ten years ago, if a psychiatrist had suggested combining Transcranial Magnetic Stimulation with a psychedelic-class medicine to treat severe depression, most colleagues would have raised eyebrows. Today, this combination — or something very close to it — is quietly becoming one of the most promising frontiers in modern psychiatry. Not because either treatment is a miracle, but because they act on fundamentally different mechanisms and appear to complement each other in ways that neither alone can achieve.
For patients with severe, chronic, or treatment-resistant depression — the very group for whom conventional medication has failed to produce lasting relief — the discussion of TMS and Psychedelic in Depression treatment as combined tools is one of the most important conversations happening in psychiatry today. I want to walk through what we know, what we are still learning, and what this means practically for Indian patients considering advanced treatment options.
Two Fundamentally Different Tools
Transcranial Magnetic Stimulation works by delivering precisely targeted magnetic pulses to specific brain regions, gradually retraining the circuits involved in mood regulation. It is an outside-in intervention. The pulses are applied externally, over a course of weeks, and the change happens through cumulative effect.
Psychedelic-assisted therapy — using medicines like ketamine (a dissociative with rapid antidepressant properties) or, in research settings, classical psychedelics such as psilocybin — works by producing a brief, chemically-mediated state of heightened neuroplasticity. During this window, which typically lasts hours to days after administration, the brain is unusually receptive to change.
Both are forms of brain stimulation for depression, broadly speaking. But they work through different receptors, different circuits, and different timeframes. This is why the idea of combining them is so interesting.
Why Combining TMS with Psychedelic Therapy Makes Mechanistic Sense
The theory behind combining these treatments is elegant. TMS opens a window of neuroplasticity through repeated stimulation over weeks. Psychedelic-assisted therapy — especially ketamine — opens a much more intense but briefer window through a single session. When both are used thoughtfully, the brain is placed into a plastic state for longer and by more than one mechanism at once.
More practically, the two treatments target different aspects of depression that often coexist. TMS is particularly effective at addressing the cognitive and motivational features — the executive dysfunction, the low drive, the reduced pleasure. Ketamine and related medicines are particularly effective at rapidly reducing suicidal thinking and lifting the emotional weight of a depressive episode. A patient with both features may benefit from both tools.
There is also the practical reality of timeline. Ketamine can produce meaningful antidepressant relief within twenty-four to seventy-two hours; TMS typically takes two to three weeks to show its effect. For a patient in acute distress, a course structured around initial ketamine sessions followed by TMS for durable consolidation offers both the speed the patient needs and the durability the treatment plan requires.
What the Research Actually Shows
I want to be careful here because the field is moving fast and it is easy to overstate the evidence.
The combined use of ketamine and TMS is supported by a growing body of case series, open-label studies, and increasingly by controlled trials. Response rates in treatment-resistant depression appear to be higher with combined protocols than with either treatment alone in comparable populations. The optimal sequencing — whether to use ketamine first and TMS afterwards, whether to overlap the two, whether to alternate — is still being worked out, and the answer likely depends on the specific patient.
For classical psychedelics such as psilocybin, the evidence base is earlier but promising. FDA-approved clinical trials of psilocybin for depression have shown remarkable response rates in treatment-resistant patients. Combined psilocybin-TMS protocols are being studied in research settings in the United States and Europe. In India, classical psychedelics are not currently a legal clinical option, and I want to be clear-eyed about that in this discussion.
For ketamine specifically — which is legal, available, and delivered in medical settings in India — the combination with TMS is already a clinical reality at leading centres, and it is one of the treatments we offer at Mind Brain Institute for appropriate patients.
Is Psychedelic Therapy Approved for Depression Treatment in India?
This is where the practical answer differs sharply from what patients read in international news articles.
Ketamine-assisted therapy — using medical ketamine at sub-anaesthetic doses in a clinical setting under psychiatric supervision — is a legitimate and legal clinical option in India. Ketamine is on the World Health Organization’s list of essential medicines, has been used in medical practice worldwide since 1970, and its use in psychiatric treatment is well-supported. At Mind Brain Institute we deliver ketamine-assisted therapy following the same international clinical framework used at licensed US ketamine clinics.
Classical psychedelics — psilocybin, LSD, and MDMA — remain controlled substances in India and are not currently a legal clinical option. When international headlines discuss “psychedelic therapy for depression”, they often mean protocols using these substances, and Indian patients should understand that these are not available to them here regardless of the media coverage.
When we discuss combining TMS with psychedelic therapy in the Indian context, the practical reality is TMS combined with medical ketamine-assisted therapy — which is the combination that has the most established clinical evidence in any case, and which is now being delivered at leading Indian centres. Learn more about our TMS therapy →
Who Benefits from TMS and Ketamine-Assisted Combination Treatment?
Combination protocols are not appropriate for every patient. In our practice we consider combined treatment particularly for:
- Severe treatment-resistant depression — patients who have failed multiple medication trials and standard TMS or ketamine alone
- Patients with active suicidal thinking who need the rapid onset of ketamine plus the durable maintenance of TMS
- Patients with depression and significant trauma comorbidity — where ketamine-assisted therapy for the trauma is combined with TMS for the depression
- Patients seeking to consolidate a partial ketamine response — where ketamine has produced meaningful but incomplete relief and TMS can extend and deepen it
- Patients seeking a shorter overall treatment timeline than either standalone approach
For patients whose depression is well-managed on medication, or who have not tried standard TMS or ketamine alone, combined protocols are usually not the right starting point. We build up to combination treatment only when the case merits it.
Is TMS Therapy Safer Than Medication-Based Depression Treatment?
Comparing the safety profiles honestly:
TMS therapy has one of the strongest safety records in modern psychiatry. Common side effects — scalp tenderness, occasional post-session headache — are mild and self-limiting. There is no medication, no dependency, no long-term cognitive impact. Seizure risk is under one in thirty thousand sessions.
Ketamine-assisted therapy used in a proper clinical setting — sub-anaesthetic doses, in-clinic delivery, integrated with psychotherapy — has a strong safety profile. Common effects during the session (dissociation, mild blood pressure elevation, occasional nausea) resolve within an hour. The addiction concern that surrounds recreational ketamine use is meaningfully lower in medically supervised, clinically dosed treatment.
Standard antidepressant medication is not “unsafe” — it is a well-established treatment used successfully by millions of patients. But it does produce systemic side effects — weight gain, sexual dysfunction, sedation, emotional blunting — that TMS and controlled ketamine do not. For patients who have not tolerated antidepressants, TMS and ketamine-assisted therapy are meaningfully better tolerated.
Neither combination nor individual advanced treatments are risk-free. But the risk-benefit calculation for patients with severe depression that has not responded to conventional treatment is often clearly in favour of exploring advanced options.
Modern Psychiatric Treatment Options for Severe Cases
For patients with depression treatment for severe cases — the population where combined TMS and ketamine-assisted therapy is most relevant — the modern treatment landscape now includes:
- Standard antidepressant medication at optimised doses
- Cognitive behavioural therapy and other structured psychotherapies
- Standard rTMS for the outpatient population
- Deep TMS for OCD and specific severe presentations
- Ketamine-assisted therapy for rapid-acting antidepressant effect
- Intranasal esketamine (Spravato) for treatment-resistant depression
- Combined TMS and ketamine-assisted protocols for the most complex cases
- ECT for the most severe inpatient cases where other treatments have failed
This is a substantially broader toolkit than the one that existed even ten years ago. It is one of the reasons why the term treatment-resistant depression therapy is starting to feel like an outdated designation — the treatments that used to be considered last-resort are now routinely available, and the outcomes achievable with them are meaningfully better than the “treatment-resistant” label suggests. Explore our depression treatment options →
The Future of Depression Treatment
Where is this all going? A few clear directions.
Precision medicine. QEEG-guided targeting, MRI-guided targeting, and biomarker-informed protocol selection are moving from research settings into routine practice. The idea that we should choose the right treatment for each patient based on measurable features of their biology — rather than by trial and error — is not aspirational anymore.
Combination protocols. TMS with ketamine, TMS with esketamine maintenance, TMS with psychotherapy, and eventually TMS with classical psychedelics (in jurisdictions where they become legal) will increasingly be the norm for complex cases.
Shorter, more intensive courses. Accelerated TMS protocols compress four to six weeks into one to two weeks. Single-day ketamine sessions replace multi-week medication trials. The patient’s total time investment is compressing.
Better maintenance. The question after successful acute treatment is how to prevent relapse. Combined approaches — periodic ketamine maintenance combined with intermittent TMS boosters and durable psychotherapy — are emerging as the answer.
For patients now, the practical takeaway is this: if you have severe or treatment-resistant depression, and you have been told that nothing else is available, that is almost certainly no longer true.
Frequently Asked Questions
- What is combination therapy using TMS and psychedelic treatment for depression? Combination therapy pairs TMS — which uses magnetic pulses to gradually retrain mood-regulation circuits — with psychedelic-assisted therapy, most commonly medical ketamine, which produces rapid neuroplasticity through a different mechanism. The combination gives the brain both the intensity of ketamine’s rapid effect and the durability of TMS’s cumulative effect, and appears to produce higher response rates than either treatment alone in comparable populations.
- Can TMS and psychedelic therapy work better together for depression? Yes, for appropriate patients. TMS and ketamine-assisted therapy act on different receptors and different circuits, and they open windows of neuroplasticity at different timeframes. For severe or treatment-resistant depression, the growing evidence base — case series, open-label studies, and increasingly controlled trials — suggests better response and remission rates with combined protocols than with either alone. Optimal sequencing depends on the specific patient.
- Is TMS therapy safer than medication-based depression treatment? TMS has a distinctly different safety profile from antidepressant medication. Where antidepressants can produce weight gain, sexual dysfunction, sedation, and emotional blunting, TMS’s side effects are limited to mild scalp tenderness and occasional short-lived headache. Neither is universally “safer” — antidepressants are well-established and highly effective for many patients — but for patients who have not tolerated medication, TMS is meaningfully better tolerated.
- Who can benefit from TMS and psychedelic-based depression treatment? Patients with severe or treatment-resistant depression who have failed multiple medication trials, patients with active suicidal thinking who need rapid intervention, patients with depression and significant trauma comorbidity, patients seeking to consolidate a partial response to either treatment alone, and patients seeking a shorter overall treatment timeline than either standalone approach.
- Is psychedelic therapy approved for depression treatment in India? Medical ketamine-assisted therapy — using sub-anaesthetic doses of ketamine in a clinical setting under psychiatric supervision — is a legitimate and legal clinical option in India. Classical psychedelics such as psilocybin and MDMA are controlled substances and are not currently legal for clinical use in India, regardless of what international news coverage may suggest. When we discuss combined TMS-psychedelic treatment in the Indian context, we mean TMS combined with medical ketamine-assisted therapy.
